Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-CAR T Cells in Brain/Leptomeningeal Metastases From HER2 Positive Cancers
NCT03696030Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Nov 2018
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of HER2-CAR T cells in HER2-positive breast cancer, brain metastases and leptomeningeal metastases (LM) (2 arms), sponsored by City of Hope. Primary endpoints: Incidence of dose limiting toxicities and Number of participants with treatment related adverse events up to 15 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
HER2-CAR T cells
03
Conditions
HER2-positive breast cancerbrain metastasesleptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT03696030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696030.